Myelofibrosis Clinical Trials in Bologna
11 recruitingBologna, Italy
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Phase 1Phase 2
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Myelofibrosis (MF)
iOnctura26 enrolled11 locationsNCT06887803
Recruiting
Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Phase 2
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Myelofibrosis
Takeda135 enrolled46 locationsNCT05037760
Recruiting
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Myelofibrosis
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS617 enrolled36 locationsNCT06533813
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135
Recruiting
Phase 2
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Myelofibrosis
Ryvu Therapeutics SA230 enrolled18 locationsNCT06397313
Recruiting
Phase 1Phase 2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc.70 enrolled19 locationsNCT05280509